2026 06 11 Subcutaneous Infusions in Hospice and Palliative Settings

Value of the Information & Strength of the Argument

The lecture provides valuable, practical information for clinicians, synthesizing historical context, clinical evidence, and personal experience. The argumentation is well-structured, comparing SQ and IV routes systematically and addressing both benefits and limitations. The speaker supports her points with references to specific studies, though she does not provide full citations. She also acknowledges uncertainties and areas lacking robust evidence, such as the use of methadone subcutaneously, demonstrating a balanced and evidence-based approach.

Scientific Rigor, Source Quality, Title Accuracy

The lecture demonstrates a reasonable level of scientific rigor, referencing several peer-reviewed studies and clinical guidelines. However, the speaker does not provide complete citations, making it difficult to verify all sources. The title accurately reflects the content, and the presentation is well-organized. The speaker’s clinical experience adds credibility, but the lack of detailed references and the reliance on anecdotal evidence in some areas slightly reduce the overall rigor.

The title accurately reflects the content, which focuses on subcutaneous infusions in hospice and palliative care.

7/10

The lecture is based on clinical experience and references several studies, but lacks detailed citations and rigorous peer-review. The speaker acknowledges limitations and uncertainties, and provides practical guidance.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and objectives of the lecture.
• 02:00History of subcutaneous infusions, including hypodermoclysis and the invention of the hollow needle.
• 05:00Anatomy of subcutaneous tissue and needle placement sites.
• 10:00Equipment used for subcutaneous infusions, including needle gauges and cannulas.
• 15:00Comparison of subcutaneous vs IV infusions: benefits and limitations.
• 20:00Medications commonly used via subcutaneous infusions, including opioids and benzodiazepines.
• 25:00Discussion of methadone's unique challenges and potential solutions.
• 30:00Review of studies supporting CSCI, including JAMA Internal Medicine 2018 and BMC Palliative Care 2020.
• 35:00Detailed discussion of dexmedetomidine (Precedex) for subcutaneous infusion, including dosing and clinical application.
• 40:00Sharing of a dexmedetomidine guideline and practical tips for implementation.

• JAMA Internal Medicine 2018 study on CSCI — Referenced in the lecture as showing improved uptake of CSCI and improved pain scores.
• BMC Palliative Care 2020 study on CSCI — Referenced as showing CSCI is effective in reducing pain in dying patients without increased adverse effects.
• Systematic review of 18 studies in Palliative Medicine 2011 — Referenced as finding no significant difference in efficacy between IV and subcutaneous opioids for cancer pain.

• JAMA Internal Medicine 2018 study on CSCI — Supports the effectiveness of CSCI in improving pain management and reducing IV use.
• BMC Palliative Care 2020 study on CSCI — Confirms the safety and efficacy of CSCI in dying patients.
• Systematic review in Palliative Medicine 2011 — Finds no significant difference between IV and subcutaneous opioids for cancer pain.

• Potential concerns with subcutaneous methadone — The lecture notes that methadone is associated with more frequent local skin irritation, and some studies recommend adding hyaluronidase, which may complicate infusion rates.